Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.150
+0.040 (3.60%)
At close: Sep 5, 2025, 4:00 PM
1.160
+0.010 (0.87%)
After-hours: Sep 5, 2025, 7:37 PM EDT
Allogene Therapeutics Employees
As of December 31, 2024, Allogene Therapeutics had 229 total employees, including 226 full-time and 3 part-time employees. The number of employees decreased by 4 or -1.72% compared to the previous year.
Employees
229
Change (1Y)
-4
Growth (1Y)
-1.72%
Revenue / Employee
n/a
Profits / Employee
-$1,034,533
Market Cap
255.16M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 229 | -4 | -1.72% |
Dec 31, 2023 | 233 | -128 | -35.46% |
Dec 31, 2022 | 361 | 51 | 16.45% |
Dec 31, 2021 | 310 | 45 | 16.98% |
Dec 31, 2020 | 265 | 59 | 28.64% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALLO News
- 10 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conference - GlobeNewsWire
- 22 days ago - Allogene Therapeutics: Important Catalysts Guided For Early 2026 - Seeking Alpha
- 23 days ago - Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 5 weeks ago - Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - GlobeNewsWire
- 3 months ago - Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha